Evidence map›Paper›PMID 41388019›Full record

ArticleNature communications2025

Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigens.

Denise Chac, Frederick J Heller, Hasan Al Banna, M Hasanul Kaisar, Susan M Markiewicz, Emily L Pruitt, Fahima Chowdhury, Taufiqur R Bhuiyan, Afroza Akter, Ashraful I Khan and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Denise ChacDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-4183-3899
Frederick J HellerDuke University School of Medicine, Durham, NC, USA.
Hasan Al BannaInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.ORCID http://orcid.org/0000-0001-7475-6706
M Hasanul KaisarInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.ORCID http://orcid.org/0009-0001-6531-1817
Susan M MarkiewiczDepartment of Medicine, University of Washington, Seattle, WA, USA.
Emily L PruittDepartment of Medicinal Chemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9522-4311
Fahima ChowdhuryInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.
Taufiqur R BhuiyanInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.
Afroza AkterInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.
Ashraful I KhanInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.
Mia G DumayasDepartment of Medicine, University of Washington, Seattle, WA, USA.
Amelia RiceDepartment of Medicine, University of Washington, Seattle, WA, USA.
Polash Chandra KarmakarInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.
Pinki DashInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.ORCID http://orcid.org/0009-0009-2367-7368
Regina C LaRocqueDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Edward T RyanDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Libin XuDepartment of Medicinal Chemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1021-5200
Samuel S MinotBioinformatics Core, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1639-3905
Jason B HarrisDepartment of Pediatrics, Harvard Medical School, Boston, MA, USA.
Firdausi QadriInfectious Diseases Division, International Centre for Diarrheoal Disease Research, Dhaka, Bangladesh.ORCID http://orcid.org/0000-0002-8928-9888
Ana A WeilDepartment of Medicine, University of Washington, Seattle, WA, USA. anaweil@uw.edu.ORCID http://orcid.org/0000-0002-6170-4306

Funding

Immune Responses to Vibrio cholerae infection and vaccination in HaitiR01AI099243 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B, IVERS, LOUISE C. · 2012 to 2022
$7.9M
ACADEMIC PEDIATRIC INFECTIOUS DISEASET32HD007233 · NICHD · SEATTLE CHILDREN'S HOSPITAL · PI KEVIN B URDAHL · 1985 to 2026
$6.7M
Training program in vaccine development and public healthD43TW005572 · FIC · MASSACHUSETTS GENERAL HOSPITAL · PI QADRI, FIRDAUSI, RYAN, EDWARD T. · 2000 to 2025
$5.4M
Contribution of altered lipid metabolism to resistance to cell envelope-targeting antimicrobials in MRSAR01AI136979 · NIAID · UNIVERSITY OF WASHINGTON · PI Brian James Werth, Libin Xu · 2018 to 2026
$4.1M
Innate and early B cell responses to V. choleraeR01AI103055 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B · 2014 to 2018
$3.9M
O-Specific Polysaccharide Responses and CholeraR01AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2014 to 2018
$3.7M
Statistical methods to enhance reproducible microbiome discoveryR35GM133420 · NIGMS · UNIVERSITY OF WASHINGTON · PI Amy D Willis · 2019 to 2026
$2.8M
The gut microbiome and susceptibility to Vibrio choleraeK08AI123494 · NIAID · UNIVERSITY OF WASHINGTON · PI WEIL, ANA A · 2016 to 2020
$967k
Humoral and adaptive immune responses study in Vibrio cholerae infectionK43TW010362 · FIC · INTERNATIONAL CTR/DIARRHOEAL DIS RES · PI BHUIYAN, MD TAUFIQUR RAHMAN · 2016 to 2020
$359k
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01 106878Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01 AI AI136979Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) T32HD007233FIC NIH HHS D43 TW005572FIC NIH HHS K43 TW010362NIAID NIH HHS K08 AI123494NIAID NIH HHS R01 AI099243NIAID NIH HHS R01 AI103055NIAID NIH HHS R01 AI106878NIAID NIH HHS R01 AI136979NICHD NIH HHS T32 HD007233NIGMS NIH HHS R35 GM133420
6 · The paper itself

Abstract

The degree of protection conferred after receiving an oral cholera vaccine (OCV) varies based on age, prior exposure to Vibrio cholerae, and unknown factors. Recent evidence suggests that the microbiota may mediate some of the unexplained differences in oral vaccine responses. Here, we use metagenomic sequencing of the fecal microbiota at the time of vaccination and relate microbial features to immune responses after OCV using a reference-independent gene-level method. We find that the presence of sphingolipid-producing bacteria is associated with the development of protective immune responses after OCV. We test these associations by stimulating human macrophages with Bacteroides xylanisolvens metabolites and find that sphingolipid-containing extracts increase innate immune responses to OCV antigens. Our findings demonstrate a new analytic method for translating metagenomic sequencing data into strain-specific results associated with a biological outcome, and in validating this tool, we identify that microbe-derived sphingolipids impact immune responses to OCV antigens.

Indexed as

CholeraCholera VaccinesGastrointestinal MicrobiomeImmunity, InnateSphingolipidsAdministration, OralAdultBacteroidesFecesFemaleHumansMacrophagesMaleVibrio choleraeCholera VaccinesSphingolipids

Identifiers

PMID41388019
PMCPMC12816596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.